Browse by ▼

Biogen Idec

  • Flush With Cash, Elan Goes on a Buying Spree

    By Diane Alter - May 20, 2013 | Tickers: BIIB, ELN, NVS

    Call it the luck of the Irish.

    Prospects have been glum for Elan Corp (NYSE: ELN), but the Irish pharmaceutical company is showing some real promise.

    After suffering a serious setback last July, when results for bapineuzumab, an Alzheimer’s therapy in development with Pfizer and Johnson & Johnson, were disappointing, many questioned its survival as a stand alone company. 

    You see, the failure of that drug left Elan with just more »

  • 4 Bio Stocks to Buy Today

    By Casey Walters - May 1, 2013 | Tickers: ARNA, BIIB, BPAX, CELG

    Bio stocks can be a gamble. When they fall, companies in this particular industry can fall hard, especially if the news is really bad or expectations were hyped beyond reality. A few months ago, Peregrine Pharmaceuticals dropped 78% in one day after the company disclosed that its stellar Phase II data for lung cancer drug ‘bavituximab’ was not valid.

    Does that mean bio stocks are a ‘no-go?' Far from it more »

  • An Elite Investor Is Bullish on This Basket of Stocks

    By Meena Krishnamsetty - April 30, 2013 | Tickers: ADS, BIIB, EQIX, MPC, V

    With roughly $2.5 billion in assets under management, Navellier & Associates is a team of about twelve investment professionals who employ quantitative and fundamental analysis. Headed by market veteran and educator Louis Navellier, the fund recently released its 13F filing for Q1 2013, outlining its latest holdings and market moves. We have used these filings to discern a small-cap strategy that has returned 37% to investors since its debut in more »

  • Growth Opportunities but Uncertainty Around Core Drug

    By Mike Thiessen - April 28, 2013 | Tickers: BIIB, CELG, SPPI

    Spectrum Pharmaceuticals (NASDAQ: SPPI) appears relatively cheap versus its peers with a P/E of slightly under 5 and return metrics (ROA, ROE and ROI) that are almost double that of other players. There may be an opportunity with Spectrum. While low P/E multiples are not a very good comparison metric for small- and mid-cap pharmaceuticals, discounted cash flow is more relevant since the stocks are tied to future more »

  • Buybacks, Takeovers and a Potentially Lucrative Drug

    By Mike Thiessen - April 24, 2013 | Tickers: BIIB, ELN, PFE

    Irish drug-maker Elan Pharmaceuticals (NYSE: ELN) has been at the center of fervent speculation from longs and shorts alike. After offloading a potential blockbuster drug called Tysabri to a smaller competitor, the company has been fighting off a takeover bid from privately held Royalty Pharma. While it is entirely possible that Elan will eventually agree to be taken private by Royalty, both companies have refused to compromise on key aspects more »

  • Why Elan Shouldn’t Take Royalty Pharma’s Sweetened Bid

    By Diane Alter - April 16, 2013 | Tickers: BIIB, ELN, PRTA

    After years of being plagued by a waning stock price, FDA regulatory issues and safety concerns over its blockbuster drug, its finally good to be Elan Corp. (NYSE: ELN).

    Shunning a February $11 per share takeover bid from U.S. based pharmaceutical investment firm Royalty Pharma, Irish based Elan got a sweetened offer of up to $12 a share. The new deal values Elan at $7.3 billion, up from more »

  • Why Elan Shouldn’t Take Royalty Pharma’s Sweetened Bid

    By Diane Alter - April 16, 2013 | Tickers: BIIB, ELN, PRTA

    After years of being plagued by a waning stock price, FDA regulatory issues and safety concerns over its blockbuster drug, its finally good to be Elan (NYSE: ELN).

    Shunning a February $11 per share takeover bid from U.S. based pharmaceutical investment firm Royalty Pharma, Irish based Elan got a sweetened offer of up to $12 a share. The new deal values Elan at $7.3 billion, up from $6 more »

  • Why Elan Shouldn’t Take Royalty Pharma’s Sweetened Bid

    By Diane Alter - April 16, 2013 | Tickers: BIIB, ELN, PRTA

    After years of being plagued by a waning stock price, FDA regulatory issues and safety concerns over its blockbuster drug, its finally good to be Elan (NYSE: ELN).

    Shunning a February $11 per share takeover bid from U.S. based pharmaceutical investment firm Royalty Pharma, Irish based Elan got a sweetened offer of up to $12 a share. The new deal values Elan at $7.3 billion, up from $6 more »

  • What Goes up Must Come Down

    By Shas Dey - April 16, 2013 | Tickers: AMGN, BIIB, CELG, GILD

    Biogen Idec (NASDAQ: BIIB) is one of those rare companies in the healthcare sector whose stock has relentlessly outperformed the broader market continuously for as long as one can remember. Year-to-date, it has gained almost 33% against less than 12% of S&P 500. Over five years, it has returned 202%. It has even outperformed the Healthcare SPDR ETF by almost 100%.

    On March 27, 2013, another dimension was added more »

  • Adage Capital Management Owns 5.4% of This Biotech Stock

    By Meena Krishnamsetty - April 10, 2013 | Tickers: ABT, AMRN, BIIB, DNDN, MDVN

    According to a 13G filed with the SEC, Adage Capital Management, a large hedge fund managed by Phil Gross and Robert Atchinson, owns just over 4 million shares of Medivation (NASDAQ: MDVN), a $3.6 billion market cap biotechnology company. Our database of 13F filings shows Adage with a position of 2.1 million shares as of the beginning of January, so in the last three months the fund has more »

  • Adage Capital Management Owns 5.4% of This Biotech Stock

    By Meena Krishnamsetty - April 8, 2013 | Tickers: ABT, AMRN, BIIB, DNDN, MDVN

    According to a 13G filed with the SEC, Adage Capital Management, a large hedge fund managed by Phil Gross and Robert Atchinson, owns just over 4 million shares of Medivation (NASDAQ: MDVN), a $3.6 billion market cap biotechnology company. Our database of 13F filings shows Adage with a position of 2.1 million shares as of the beginning of January, so in the last three months the fund has more »

  • Does Spectrum's Q4 Earnings Make It a Buy?

    By Shas Dey - April 1, 2013 | Tickers: BIIB, RHHBY, SPPI

    On 03/12/13, Spectrum Pharmaceuticals (NASDAQ: SPPI) announced its Q42012 results, and its shares declined 35% to $8, setting a new low for the company.

    Spectrum is a biotechnology company with integrated commercial and drug development operations with a focus in hematology and oncology. It markets three oncology drugs: Fusilev, Folotyn, and Zevalin. It has a strong track record of licensing and acquiring differentiated drugs. It also has a more »

  • How Safe is AbbVie from Niacin’s Woes?

    By Shas Dey - March 21, 2013 | Tickers: ABBV, BIIB, MRK, NBIX

    Niacin is a B vitamin essential for the normal function of the nervous system and the gastrointestinal tract, and used for boosting high density lipoprotein (HDL), the “good cholesterol." Although OTC versions of Niacin are available as daily vitamin supplements, a prescription form called Niaspan from AbbVie Inc. (NYSE: ABBV) is a widely prescribed drug for heart patients. However, recent developments do not look too good for the drug.

    More more »

  • These Drug Partners are Headed in Opposite Directions

    By Robert Hanley - March 7, 2013 | Tickers: BIIB, ELN, TEVA

    Biogen Idec (NASDAQ: BIIB) and Elan Pharmaceuticals (NYSE: ELN) have partnered for more than a decade to win a big share of the multiple sclerosis (MS) drug market.  While their drug Tysabri has achieved some commercial success, everyone is chasing Teva Pharmaceuticals (NYSE: TEVA) and its MS drug Copaxone that controls roughly 40% of the domestic market.  Now, though, it looks like Biogen wants to go it alone, with a more »

  • Elan Received Buyout Bid Before Buyback

    By Diane Alter - February 25, 2013 | Tickers: BIIB, ELN, PRTA

    When Elan (NYSE: ELN) sold its stake in the blockbuster selling multiple sclerosis drug Tysabri to partner Biogen (NASDAQ: BIIB) in early February, many investors at both companies were left questioning the deal and the motive.

    Dublin, Ireland based Elan pocketed $3.25 billion in the sale (on which it will pay little tax) and also inked a royalty payment plan for future sales of the dynamic drug. The hefty more »

  • Tysabri Brings Big Upside Potential To This Biotech

    By Jordo Bivona - February 21, 2013 | Tickers: BIIB, GILD, TEVA

    Biogen Idec (NASDAQ: BIIB) recently reported its results and provided an update on its drug development pipeline. This, together with its acquisition of the full rights to Tysabri, gives us a good chance to evaluate its investment potential.

    Biogen Idec has announced results for the fourth quarter of 2012 as well as the full year. Total revenues for the full year grew 9% to $5.5 billion compared to 2011 more »

  • A Strong Growth Opportunity In Multiple Sclerosis

    By Jordo Bivona - February 19, 2013 | Tickers: BIIB, SNY, TEVA

    Biogen Idec (NASDAQ: BIIB) has just moved to reinforce its dominance in the multiple sclerosis treatment market by striking a deal to buy the 50% rights to Tysabri that it does not own from its partner Elan. Biogen's MS drugs account for about 30% of the roughly $12 billion global MS market, and Tysabri is regarded as the most effective treatment, not to mention the least vulnerable to generic more »

  • How to Get a New-ish Drug to Market in 20% Less Time at 2% the Cost

    By Nick Slepko - February 19, 2013 | Tickers: BIIB, LLY, JNJ, MRK, NVS

    Massachusetts-based BioChemics is a private pharmaceutical company that has developed a number of new drug delivery systems which allow treatments to be administered through the skin.  The company’s Founder, Chairman, President, and CEO John Masiz discusses the pharmaceutical and biotech industries. 

    [continued from Smart Drugs: A New Hope]

    Nick Slepko:  According to the Wall Street Journal, seven million Americans spend over USD 25 billion every year on chronic wound more »

  • Why Elan Cut Its Ties To Tysabri

    By Diane Alter - February 12, 2013 | Tickers: BIIB, ELN, PRTA

    Editor's Note: The original article referenced shareholders would receive one share of Prothena for every share of Elan. That was incorrect, shareholders received one share of Prothena for 41 shares of Elan. This version has been corrected and Motley Fool apologizes for the error.

    Elan (NYSE: ELN) just announced a restructuring of its Tysabri collaboration with Biogen Idec (NASDAQ: BIIB) going from a 50/50 collaboration to an upfront more »

  • Biogen Idec a Strong Buy on Pipeline Prospects

    By Jordo Bivona - January 29, 2013 | Tickers: BIIB, TEVA

    Dexpramipexole, an experimental drug to treat Lou Gehrig’s disease, has failed to work in a late-stage clinical trial, the drug’s developer, Biogen Idec (NASDAQ: BIIB) said. Medical experts and patients had hoped it would work to treat the poorly understood and fatal illness. The company said it would discontinue work on the drug because it was not effective in slowing the loss of muscular function nor in prolonging more »

  • Page 1 of 2